The COVID-19 pandemic was the third leading cause ... 2, the dominant strain last spring, and the Novovax vaccine, which targets JN.1, should be effective against XEC.

There is currently no vaccine available ... omicron variant XEC rising as a fast-spreading variant slated to take over as the ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.

Ireland has reported a significant increase in cases of the new XEC Covid variant, now accounting for 20.6% of cases in ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing ...

Researchers investigate how public trust in the science of COVID-19 vaccines has changed in the United States.

More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.

The latest coronavirus strain, XEC, makes up 17%. It is another descendant from the ... insurance provider as we cannot ...

The XEC COVID-19 variant is poised to become the dominant variant worldwide. Now is a good time to get an updated COVID ...

As of late October, the CDC recommends a second dose of the 2024-2025 COVID-19 vaccine for at-risk groups. Here's what you ...